Botulinum toxin “patch” use
Do not use a “botulinum toxin type A transdermal patch” at all—no such FDA‑approved patch exists; botulinum toxin A should be administered only by injection per the drug label, and transdermal delivery remains experimental. 1, 2
What to do (to protect morbidity, mortality, and quality of life)
- If your intent is therapeutic/cosmetic BoNT‑A:
- Use labeled intramuscular injections with onabotulinumtoxinA per FDA instructions (doses, dilution, needle, and injection sites). Do not attempt any patch application. 1
- If your concern is botulism exposure/illness:
- This is treated with IV botulinum antitoxin (BAT), not with any BoNT‑A product or patch. Early antitoxin reduces paralysis progression and ICU time. Contact public health/CDC immediately for BAT. 3
Why a “24‑hour toxin patch” is inappropriate
- FDA labels specify BoNT‑A is for injection; units are not interchangeable and transdermal use is unsupported. Using a patch risks uncontrolled absorption, diffusion to unintended muscles, and serious adverse effects. 1
- Transdermal BoNT‑A is investigational (animal and formulation studies only); no approved human patch products exist. 2, 4
- Transdermal systems favor small molecules; BoNT‑A is a large protein and does not reliably cross intact skin. 5, 6
If someone already applied a “toxin patch”
- Remove it immediately; wash the area with soap and water.
- Monitor for systemic botulinum effects (ptosis, dysphagia, dysarthria, dyspnea, descending weakness). If present, urgently contact health department/CDC for botulism consultation and BAT. Early treatment improves outcomes. 3